|
|
Volumn 34, Issue 1, 2002, Pages 104-
|
|
Use of reduced dose of OKT3 (2.5 mg) after renal transplantation
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZATHIOPRINE;
CD3 ANTIGEN;
CREATININE;
GANCICLOVIR;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
OKT 3;
STEROID;
TACROLIMUS;
ARTICLE;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
CREATININE BLOOD LEVEL;
CYTOMEGALOVIRUS INFECTION;
FLOW CYTOMETRY;
FOLLOW UP;
GRAFT SURVIVAL;
HUMAN;
KIDNEY GRAFT REJECTION;
LEUKOCYTE COUNT;
MAJOR CLINICAL STUDY;
MONONUCLEAR CELL;
PRIORITY JOURNAL;
TREATMENT FAILURE;
ACUTE DISEASE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FOLLOW-UP STUDIES;
GRAFT REJECTION;
HUMANS;
KIDNEY TRANSPLANTATION;
MUROMONAB-CD3;
REOPERATION;
RETROSPECTIVE STUDIES;
TACROLIMUS;
TIME FACTORS;
TREATMENT FAILURE;
|
|
EID: 0036223914
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(01)02688-4 Document Type: Article |
|
Times cited : (3)
|
|
References (3)
|
